Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) reported no changes to its share capital structure for the month ended 30 April 2026.

Authorised and Issued Capital • Total authorised/registered share capital remained at RMB 2.67 billion shares, split into 2.12 billion A-shares and 0.55 billion H-shares, each with a par value of RMB 1.00.

• Issued shares (excluding treasury shares) were steady at 2.10 billion A-shares and 540.97 million H-shares. Treasury holdings also stayed unchanged at 19.91 million A-shares (0.94 % of total A-share capital) and 10.97 million H-shares (1.99 % of total H-share capital).

Treasury Movements and Capital Raising • No new shares were issued, repurchased, cancelled, or transferred from treasury during April. • Consequently, the company raised no capital from option exercises or other equity-linked instruments in the period.

Equity-Based Incentives • A-share stock options outstanding under the 2025 A-Share Option Scheme totalled 4.45 million, equivalent to 0.21 % of issued A-shares. No options were exercised or cancelled in April. • Under the 2025 H-Share Restricted Share Unit (RSU) Scheme, 10.38 million RSUs remained outstanding, representing 1.92 % of issued H-shares. No RSUs vested or were cancelled during the month.

Regulatory Compliance • The company confirmed full compliance with the Hong Kong Stock Exchange’s minimum 5 % public-float requirement for its H-share class. • All board authorisations and regulatory filings related to outstanding equity-linked schemes are in place, with no additional conditions pending.

Key Takeaway April 2026 saw Fosun Pharma maintain a stable capital base with zero share issuance or treasury activity, while modest levels of employee equity incentives remain outstanding. The unchanged structure and confirmed public-float adherence underscore the company’s steady shareholding profile during the month.